| Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up? | |
| | |
MedLine Citation:
|
PMID: 20679886 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pegylated liposomal doxorubicin (PLD; Doxil or Caelyx) has been shown to be as effective as conventional doxorubicin, and to have a significantly better cardiac safety profile. The aim of this study was to assess the safety of delivering doses exceeding 700 mg/m of PLD to patients with solid tumors. A review of the medical records of 149 patients with a variety of solid tumors treated with PLD was performed. The findings in 12 patients who had reached or exceeded cumulative doses of 700 mg/m (median=1.071 mg/m, range 712-1856 mg/m) were reviewed. Changes in left ventricular ejection fraction (LVEF), and in clinical cardiac status were analyzed. The median age of the patients was 53.9 years and the median follow-up from the start of PLD treatment was 44.6 months. None of the 12 patients had clinical congestive heart failure secondary to cardiomyopathy. Seven of the 12 patients underwent further assessment of LVEF by echocardiography or multiple gated acquisition scan, which revealed a stable or improved ejection fraction.PLD is cardiac safe for long-term treatment of metastatic solid tumors. Its maximal cumulative dose remains undefined. Frequent determinations of LVEF, as routinely done for other anthracyclines, do not appear to have any clinical value in patient follow-up. In metastatic patients with no evidence of cardiac risk factors, it may be sufficient to measure LVEF at baseline. |
| | |
Authors:
|
Tal Grenader; Anthony Goldberg; Alberto Gabizon |
Related Documents
:
|
18471446 - Cardiac troponin i elevation in hospitalized patients without acute coronary syndromes. 8729556 - Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we i... 8190486 - Orbital polymyositis and giant cell myocarditis. 16769656 - National registry of patients with juvenile idiopathic inflammatory myopathies in hunga... 16504996 - Power doppler sonography monitoring of synovial perfusion at the wrist joints in patien... 2323256 - Apneustic breathing. a characteristic feature of brainstem compression in achondroplasia? |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Anti-cancer drugs Volume: 21 ISSN: 1473-5741 ISO Abbreviation: Anticancer Drugs Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-02 Completed Date: 2010-12-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 868-71 Citation Subset: IM |
Affiliation:
|
Department of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel. talgrenader65@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antibiotics, Antineoplastic / administration & dosage, adverse effects*, therapeutic use Dose-Response Relationship, Drug Doxorubicin / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use Drug Monitoring / methods Echocardiography Female Follow-Up Studies Humans Male Middle Aged Neoplasms / drug therapy*, pathology Polyethylene Glycols / administration & dosage, adverse effects*, therapeutic use Retrospective Studies Time Factors Ventricular Function, Left / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Polyethylene Glycols; 0/pegylated liposomal doxorubicin; 23214-92-8/Doxorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Epithelial-Myoepithelial Carcinoma With High Grade Transformation.
Next Document: Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?